Siemens Healthineers: A €6 Billion Diagnostics Exit and a Coming Spin-Off as Shares Hit Rock Bottom

Siemens Healthineers stock plunges to new lows as tariffs and currency headwinds pressure earnings, while a diagnostics divestiture and Moody's rating open new strategic paths.

The medical technology group Siemens Healthineers is navigating one of its most turbulent periods since listing, with shares plumbing fresh depths just days before a pivotal earnings release. The stock closed at €33.78 on Wednesday, marking a new 52-week low and extending its year-to-date decline to roughly 24%. That puts the equity nearly 32% below its 52-week peak of around €50.

The sell-off has been relentless — six consecutive losing sessions — and technical indicators are flashing warning signals. The relative strength index has dipped to 31.6, territory that typically suggests oversold conditions. But in the current environment, few analysts are calling a bottom.

Tariffs and Currency Headwinds Pile On

The macro backdrop has turned decisively hostile. Fresh US tariffs are expected to shave roughly €400 million off adjusted EBIT this year, while adverse currency movements could add another €200 million to €250 million in headwinds. Those numbers have weighed heavily on sentiment, even as management maintains its full-year guidance for comparable revenue growth of 5% to 6% and adjusted earnings per share between €2.20 and €2.40.

The second quarter itself is expected to come in below that range, with weakness in China's diagnostics business proving particularly stubborn. Beijing's anti-corruption campaign has centralised procurement processes and disrupted sales cycles, hitting the diagnostics segment hardest. Revenues there shrank by around 3% in the first quarter.

Morgan Stanley trimmed its price target to €41 in April — a level that still implies upside of more than 20% from current levels, but also reflects the scale of the damage already done.

Diagnostics Divestiture Takes Shape

The diagnostics business is now at the centre of two parallel narratives. Beyond the operational drag, media reports suggest management is exploring a sale to private equity investors for roughly €6 billion. Such a deal would offload the group's weakest-performing division while simultaneously helping to address a debt pile of approximately €14 billion.

The higher-margin imaging segment and the Varian cancer therapy unit would remain untouched by any disposal. The logic is straightforward: shed a drag on margins and use the proceeds to strengthen the balance sheet ahead of a broader corporate separation.

Moody's Rating Opens New Funding Options

That separation is already taking concrete form. Moody's has assigned an inaugural standalone long-term rating of A3 with a stable outlook to Siemens Healthineers. The move paves the way for independent bond issuance, severing the company's reliance on intra-group financing from parent Siemens AG, which itself carries a higher Aa3 rating.

The parent company plans to put a spin-off of 30% of its Healthineers stake to a shareholder vote at its annual general meeting in February 2027. The process is being structured under Germany's transformation law, though regulatory clearance has yet to be secured. Once the corporate guarantee for up to €13.9 billion in Healthineers debt is removed, the medical technology group will have to fund itself entirely on its own terms.

What the Q2 Numbers Need to Show

All eyes are now on 7 May, when the company releases its second-quarter results at 7:00 am CEST. The headline numbers will matter, but the real focus will be on two questions: how deep the China effect actually runs, and whether the full-year guidance can hold against the tariff and currency headwinds.

The analyst call is likely to be dominated by the timeline for the spin-off and the diagnostics sale. A formal decision on the stake reduction could come as early as 2027, but investors are looking for clearer signals on how the pieces fit together — and how long they will have to wait for the value creation story to materialise.